AZD9291 is an oral irreversible, selective mutant EGFR inhibitor with IC50 values of exon-19 deletion EGFR, L858R/T790M EGFR, and WT EGFR of 12.92, 11.44, and 493.8 nM, respectively.

 

Brand:BCM

 

Target: EGFR

 

Signaling Pathways: Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors

 

Melting Point: >188oC (dec.)

 

Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated)

 

Isomeric SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC  

 

InChIKey: DUYJMQONPNNFPI-UHFFFAOYSA-N  

 

InChI: InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)

 

Attribute
[CAS No.]	1421373-65-0
[Formula]	C28H33N7O2
[Molecular]	499.61
[Chem Name]	N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide;AZD929/Osimertinib
[Synonym]	Osimertinib; AZD9291; AZD-9291
[Storage]	Hygroscopic, -20°C Freezer. Under inert atmosphere
[EINECS]	629-848-5
[MDL No.]	MFCD27988062
[Form]	Pale Yellow to Beige Solid

Goods Tag